Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis

被引：8
作者：
Gao, Siyuan [1 ,2 ]
Zhang, Mei [1 ,2 ]
Wu, Kaishan [1 ,2 ]
Zhu, Jianhong [1 ,2 ]
He, Zhichao [1 ,2 ]
Li, Jianfang [1 ,2 ]
Chen, Chuxiong [1 ,2 ]
Qiu, Kaifeng [1 ,2 ]
Yu, Xiaoxia [1 ,2 ]
Wu, Junyan [1 ,2 ]
机构：
[1] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pharm, 107 Yanjiang West Rd, Guangzhou 510120, Peoples R China
来源：
EXPERT OPINION ON DRUG SAFETY | 2020年 / 19卷 / 05期
关键词：
Brentuximab vedotin; adverse event; lymphoma patients; meta-analysis; T-CELL LYMPHOMA; CANCER; CHEMOTHERAPY; THERAPY; PHASE-3; CD30;
D O I：
10.1080/14740338.2020.1718103
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Objectives: To assess the risk of adverse events (AEs) associated with brentuximab vedotin in lymphoma patients. Methods: Articles were retrieved from PubMed, Cochrane, and Clinicaltrials Databases to identify randomized controlled trials (RCTs) comparing brentuximab vedotin with non-brentuximab vedotin in lymphoma patients. Results: A total of 2225 patients from 4 RCTs were included. Compared with the non-brentuximab vedotin group, the brentuximab vedotin group significantly increased the risk of all-grade AEs (RR 1.05, 95% CI: 1.00-1.10), and high-grade AEs (risk ratio [RR] 1.27, 95% confidence intervals [CI]: 1.01-1.58). The brentuximab vedotin group significantly increased the risk of all-grade peripheral sensory neuropathy (RR 2.29, 95% CI: 1.23-4.26), pyrexia (RR 1.23, 95% CI: 1.05-1.44), nausea (RR 1.51, 95% CI: 1.05-2.18), vomiting (RR 1.54, 95% CI: 1.08-2.19), diarrhea (RR 1.69, 95% CI: 1.44-1.98), and alopecia (RR 1.18, 95% CI: 1.00-1.39), respectively. The brentuximab vedotin group significantly increased the risk of high-grade sensory neuropathy (RR 4.79, 95% CI: 1.46-15.75), neutropenia (RR 1.48, 95% CI: 1.01-2.18), nausea (RR 2.65, 95% CI: 1.37-5.12), vomiting (RR 2.2, 95% CI: 1.17-4.12), and diarrhea (RR 1.85, 95% CI: 1.21-2.85). Conclusion: Brentuximab vedotin increased the risk of certain AEs in lymphoma patients.
引用
收藏
页码：617 / 623
页数：7
相关论文
共 25 条
[1]   Guidance on the management of diarrhoea during cancer chemotherapy [J].
Andreyev, Jervoise ;
Ross, Paul ;
Donnellan, Clare ;
Lennan, Elaine ;
Leonard, Pauline ;
Waters, Caroline ;
Wedlake, Linda ;
Bridgewater, John ;
Glynne-Jones, Rob ;
Allum, William ;
Chau, Ian ;
Wilson, Richard ;
Ferry, David .
LANCET ONCOLOGY, 2014, 15 (10) :E447-E460
[2]   CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas [J].
Bhatt, Geetika ;
Maddocks, Kami ;
Christian, Beth .
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2016, 11 (06) :480-491
[3]   Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma [J].
Chen, Robert ;
Gopal, Ajay K. ;
Smith, Scott E. ;
Ansell, Stephen M. ;
Rosenblatt, Joseph D. ;
Savage, Kerry J. ;
Connors, Joseph M. ;
Engert, Andreas ;
Larsen, Emily K. ;
Huebner, Dirk ;
Fong, Abraham ;
Younes, Anas .
BLOOD, 2016, 128 (12) :1562-1566
[4]   Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma [J].
Connors, J. M. ;
Jurczak, W. ;
Straus, D. J. ;
Ansell, S. M. ;
Kim, W. S. ;
Gallamini, A. ;
Younes, A. ;
Alekseev, S. ;
Illes, A. ;
Picardi, M. ;
Lech-Maranda, E. ;
Oki, Y. ;
Feldman, T. ;
Smolewski, P. ;
Savage, K. J. ;
Bartlett, N. L. ;
Walewski, J. ;
Chen, R. ;
Ramchandren, R. ;
Zinzani, P. L. ;
Cunningham, D. ;
Rosta, A. ;
Josephson, N. C. ;
Song, E. ;
Sachs, J. ;
Liu, R. ;
Jolin, H. A. ;
Huebner, D. ;
Radford, J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (04) :331-344
[5]   How I diagnose and treat neutropenia [J].
Dale, David C. .
CURRENT OPINION IN HEMATOLOGY, 2016, 23 (01) :1-4
[6]   Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis [J].
Duvic, Madeleine ;
Tetzlaff, Michael T. ;
Gangar, Pamela ;
Clos, Audra L. ;
Sui, Dawen ;
Talpur, Rakhshandra .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) :3759-+
[7]   The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Product for Human Use [J].
Gravanis, Iordanis ;
Tzogani, Kyriaki ;
van Hennik, Paula ;
de Graeff, Pieter ;
Schmitt, Petra ;
Mueller-Berghaus, Jan ;
Salmonson, Tomas ;
Gisselbrecht, Christian ;
Laane, Edward ;
Bergmann, Lothar ;
Pignatti, Francesco .
ONCOLOGIST, 2016, 21 (01) :102-109
[8]   Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial [J].
Horwitz, Steven ;
O'Connor, Owen A. ;
Pro, Barbara ;
Illidge, Tim ;
Fanale, Michelle ;
Advani, Ranjana ;
Bartlett, Nancy L. ;
Christensen, Jacob Haaber ;
Morschhauser, Franck ;
Domingo-Domenech, Eva ;
Rossi, Giuseppe ;
Kim, Won Seog ;
Feldman, Tatyana ;
Lennard, Anne ;
Belada, David ;
Illes, Arpad ;
Tobinai, Kensei ;
Tsukasaki, Kunihiro ;
Yeh, Su-Peng ;
Shustov, Andrei ;
Huttmann, Andreas ;
Savage, Kerry J. ;
Yuen, Sam ;
Iyer, Swaminathan ;
Zinzani, Pier Luigi ;
Hua, Zhaowei ;
Little, Meredith ;
Rao, Shangbang ;
Woolery, Joseph ;
Manley, Thomas ;
Trumper, Lorenz ;
Aboulafia, David ;
Alpdogan, Onder ;
Ando, Kiyoshi ;
Arcaini, Luca ;
Baldini, Luca ;
Bellam, Naresh ;
Bartlett, Nancy ;
Ben Yehuda, Dina ;
Benedetti, Fabio ;
Borchman, Peter ;
Bordessoule, Dominique ;
Brice, Pauline ;
Briones, Javier ;
Caballero, Dolores ;
Carella, Angelo Michele ;
Chang, Hung ;
Cheong, June Weon ;
Cho, Seok-Goo ;
Choi, Ilseung .
LANCET, 2019, 393 (10168) :229-240
[9]   Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms [J].
Jiang, Manli ;
Bennani, N. Nora ;
Feldman, Andrew L. .
EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (03) :239-249
[10]  
Liberati A, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.b2700, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007, 10.1186/2046-4053-4-1, 10.1016/j.ijsu.2010.07.299, 10.1136/bmj.b2535, 10.1136/bmj.i4086]
123